- Home
- CCL vs ONC Comparison
CCL vs ONC Comparison
Compare CCL & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CCL | ONC |
|---|---|---|
| Founded | 1972 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.8B | 34.8B |
| IPO Year | 1987 | N/A |
Fundamental Metrics
Financial Performance| Metric | CCL | ONC |
|---|---|---|
| Price | $25.84 | $342.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 19 | 12 |
| Target Price | $33.42 | ★ $369.50 |
| AVG Volume (30 Days) | ★ 22.5M | 326.6K |
| Earning Date | 12-19-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.65 | N/A |
| EPS | ★ 1.94 | 0.29 |
| Revenue | ★ $26,230,000,000.00 | $4,998,489,124.00 |
| Revenue This Year | $7.65 | $35.34 |
| Revenue Next Year | $4.32 | $22.45 |
| P/E Ratio | ★ $13.30 | $1,157.20 |
| Revenue Growth | 7.15 | ★ 53.47 |
| 52 Week Low | $15.07 | $170.99 |
| 52 Week High | $32.80 | $385.22 |
Technical Indicators
Market Signals| Indicator | CCL | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 44.09 | 51.09 |
| Support Level | $24.65 | $322.41 |
| Resistance Level | $26.86 | $345.58 |
| Average True Range (ATR) | 1.01 | 14.51 |
| MACD | 0.02 | -2.20 |
| Stochastic Oscillator | 35.49 | 29.90 |
Price Performance
Historical ComparisonAbout CCL Carnival Corporation
Carnival is the largest global cruise company, with more than 90 ships in service. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America; P&O Cruises and Cunard Line in the United Kingdom; Aida in Germany; Costa Cruises in Southern Europe. It recently folded its P&O Australia brand into Carnival. The firm also owns Holland America Princess Alaska Tours in Alaska and the Canadian Yukon. Carnival's brands attracted 14 million guests in 2024.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.